A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

February 24, 2020

Study Completion Date

October 12, 2022

Conditions
HER2-Positive Early Breast Cancer
Interventions
DRUG

Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)

PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).

DRUG

Pertuzumab IV

Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.

DRUG

Trastuzumab IV

Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.

Trial Locations (40)

2241

Bellevue Medical Center, El-Metn

6520

Hammoud Hospital, Saida

10300

Hospital Hermanos Ameijeiras, La Habana

10400

Instituto Nacional de Oncología y Radiología (INOR), La Habana

11000

Institute of Oncology and Radiology of Serbia, Belgrade

11525

King Fahad Medical City; Gastroentrology, Riyadh

11941

King Hussein Cancer Center, Amman

15054

National Center for Cancer Care and Research, Doha

18000

Clinical Centre Nis, Clinic for Oncology, Niš

20850

Maryland Oncology Hematology, Rockville

38320

Hospital Universitario de Canarias;servicio de Oncologia, San Cristóbal de La Laguna

61615

Illinois Cancer Care, Peoria

65130

VAASAN KESKUSSAIRAALA; Onkologian poliklinikka, Vaasa

66278

Centro Médico Zambrano Hellion, Monterrey

70210

KYS Sadesairaala; Syopatautien poliklinikka, Kuopio

72189

Västmanlands sjukhus Västerås, Onkologkliniken, Västerås

75231

Texas Oncology - Dallas Presbyterian Hospital, Dallas

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology- Northeast Texas, Tyler

76000

Cuidados oncologicos, Querétaro City

77024

Texas Oncology - Memorial City, Houston

78217

USOR - Texas Oncology - San Antonio Northeast, San Antonio

80228

Rocky Mountain Cancer Center - Lakewood (West), Lakewood

8420383

Bradford Hill Centro de Investigaciones Clinicas, Recoleta

67214-3728

Cancer Center of Kansas, Wichita

C1284AEB

Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires

80510-130

Instituto de Câncer E Transplante, Curitiba

22290-160

Clinicas Oncologicas Integradas - COI, Rio de Janeiro

01236-030

Instituto de Ensino e Pesquisa Sao Lucas - IEP, São Paulo

04014-002

Núcleo de Pesquisa São Camilo; ONCOLOGIA CLINICA / QUIMIOTERAPIA, São Paulo

Unknown

Princess Margaret Hospital, Oncology; Department of Oncology, Hong Kong

Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin

Consultorio Privado (José Luis González Trujillo), León

0801

Centro Oncológico de Panamá, Panama City

0832

Centro Hemato Oncologico Panama, Panama City

1500-650

Hospital da Luz; Departamento de Oncologia Medica, Lisbon

1649-035

Hospital de Santa Maria; Servico de Oncologia Medica, Lisbon

4200-072

IPO do Porto; Servico de Oncologia Medica, Porto

03203

Hospital General Universitario de Elche; Servicio de Oncologia, Elche

118 83

Sodersjukhuset; Onkologkliniken, Stockholm

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03674112 - A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer | Biotech Hunter | Biotech Hunter